Published in Nat Rev Endocrinol on September 21, 2010
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study. PLoS One (2013) 0.83
Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag (2013) 0.80
Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. Haematologica (2012) 0.79
Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks? Ther Adv Drug Saf (2012) 0.78
Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets. Biomol Ther (Seoul) (2013) 0.77
Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol (2012) 0.75
Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care (2011) 0.75
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol (1971) 7.75
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 7.34
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet (2001) 6.38
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 5.65
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 3.88
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (2009) 3.83
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care (2003) 3.68
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med (2004) 3.34
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (2000) 3.02
Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med (2007) 2.88
Platelet activation in obese women: role of inflammation and oxidant stress. JAMA (2002) 2.79
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med (2006) 2.73
Aspirin as an antiplatelet drug. N Engl J Med (1994) 2.72
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA (1992) 2.52
Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation (2008) 2.42
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 2.20
Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci (1966) 2.13
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00
Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res (2004) 1.97
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract (2009) 1.90
Type 1 diabetes, hyperglycaemia, and the heart. Lancet (2008) 1.83
Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med (2007) 1.77
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke (1992) 1.44
Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J (2007) 1.40
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A (2002) 1.39
Methods for the measurement of platelet function. Am J Cardiol (2009) 1.36
Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med (1990) 1.32
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol (2002) 1.30
Altered platelet function in diabetes mellitus. Diabetes (1976) 1.24
On defining aspirin resistance. J Am Coll Cardiol (2005) 1.11
Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest (1990) 1.11
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost (2007) 1.11
Don't use aspirin for primary prevention of cardiovascular disease. BMJ (2010) 1.09
Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis (2009) 1.07
Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care (2009) 0.98
Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol (2003) 0.93
Frequency of aspirin resistance in a community hospital. Am J Cardiol (2006) 0.93
Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". Am Heart J (2009) 0.86
The benefit of aspirin therapy in type 2 diabetes: what is the evidence? Int J Cardiol (2008) 0.85
An editorial update: should she take aspirin? Ann Intern Med (2005) 0.82
Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res (2005) 0.81
Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care (2010) 0.80
Application of platelet function testing to the bedside. Thromb Haemost (2009) 0.78
Elevated platelet activation in type I diabetics with chronic complications under long-term near-normoglycemic control. Haemostasis (1990) 0.76
Will blocking the platelet save the diabetic? Circulation (2000) 0.76
Clinical perspectives of statin-induced rhabdomyolysis. Am J Med (2006) 3.00
Production of polyhydroxyalkanoates from waste frying oil by Cupriavidus necator. AMB Express (2011) 1.04
Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol (2010) 1.04
Addition of a clinical pharmacist to an inpatient family medicine service. Am J Health Syst Pharm (2010) 0.83
What combination therapy with a statin, if any, would you recommend? Curr Atheroscler Rep (2011) 0.81
Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D. Transl Res (2007) 0.80
Is microalbuminuria a disease? Pharmacotherapy (2012) 0.78
Pharmacotherapy for hypertension in older adults: a systematic review. Drugs Aging (2014) 0.77
Let's Get Healthy! Health awareness through public participation in an education and research exhibit. Prog Community Health Partnersh (2012) 0.77
Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol (2012) 0.75
Clinical decision making on statin drug interactions. J Am Coll Cardiol (2003) 0.75
Preparation of isomorphously substituted scandium ZSM-5 using aqueous fluoride gels. Dalton Trans (2004) 0.75
Efficient methane/nitrogen separation with low-sodium clinoptilolite. Chem Commun (Camb) (2002) 0.75
Synthesis of high silicon content SAPO(4)-5 using anionic surfactants in a hexanol/aqueous two phase media. Chem Commun (Camb) (2002) 0.75
Fluctuation Scaling, the Calibration of Dispersion, and the Detection of Differences. Anal Chem (2017) 0.75